US009409872B1

(12) **United States Patent**
**Nguyen**

(10) **Patent No.: US 9,409,872 B1**
(45) **Date of Patent: Aug. 9, 2016**

(54) **FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE**

(71) Applicant: **Mark Quang Nguyen**, San Jose, CA (US)

(72) Inventor: **Mark Quang Nguyen**, San Jose, CA (US)

(73) Assignee: **Mark Quang Nguyen**, San Jose, CA (US)

( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/623,188**

(22) Filed: **Feb. 16, 2015**

(51) **Int. Cl.**

| | |
|---|---|
| ***A61K 31/513*** | (2006.01) |
| ***C07D 239/54*** | (2006.01) |
| ***A61K 9/00*** | (2006.01) |
| ***A61K 45/06*** | (2006.01) |

(52) **U.S. Cl.**
CPC ..... ***C07D 239/54*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 31/513*** (2013.01); ***A61K 45/06*** (2013.01)

(58) **Field of Classification Search**
CPC ..... C07D 239/54
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,637,529 B2 * 1/2014 Woller ..... C07D 487/04 514/262.1

FOREIGN PATENT DOCUMENTS

DE 2012644 A1 * 9/1971 ..... C07D 213/30
JP 10001521 A * 1/1998

OTHER PUBLICATIONS

Goodman & Gilman's, Manual of Pharmacology and Therapeutics 336-348 (L.L. Bruton et al., eds., 2008).*
O.E. Lutz, 110(1) Journal of the Chemical Society, Abstracts, 73-74 (1916).*
CAS Abstract JP 10001521 A, Accession No. 1998:25419 (1998).*
T. Imagawa et al., 7 Chemistry Letters, 903-904 (1981).*
T. Kato et al., 25 Chemical & Pharmaceutical Bulletin, 491-494 (1977).*
CAS Abstract of 13 Gaodeng Xuexiao Huaxue Xuebao, 1561-1563 (1992), Accession No. 1993:517198 (1993).*
CAS Reg No. 556022-68-5 (Entered STN: Jul. 28, 2003).*
CAS Reg No. 556023-70-2 (Entered STN: Jul. 28, 2003).*
CAS Reg No. 871807-04-4 (Entered STN: Jan. 12, 2006).*

* cited by examiner

*Primary Examiner* — Alexander R Pagano

(57) **ABSTRACT**

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.

**13 Claims, No Drawings**